NRX Pharmaceuticals, Inc. Common Stock (NRXP) Stock Price
NRXPStock
$3.67+30.68%52W
Market Cap$158.90M
P/E—
PEG Ratio—
Div yield—
Beta2.04
NRXP Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)83.12%
Price vs S&P 500 (4W)-5.59%
VGM Score67.42
NRXP Earnings Surprise History
Q2 25-0.98est. -0.23
Q3 25-0.51est. -0.02
Q4 250.18est. -0.08
Q1 26-0.04est. -0.11
Q2 26-0.24est. -0.13
NRXP Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.20
4.18
4.18
4.18
Industry Peers — Pharmaceuticals(571)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
NRXPNRX Pharmaceuticals, Inc. Common Stock | — | — | B | $3.67 |
| LLYEli Lilly & Co. | D | B | B | $1233.66 |
| JNJJohnson & Johnson | D | C | B | $273.14 |
| ABBVABBVIE INC. | D | C | B | $265.79 |
| MRKMerck & Co., Inc. | D | C | A | $156.45 |
| NVSNovartis AG | C | C | C | $159.98 |
| AZNAstraZeneca PLC | C | B | C | $169.66 |
| NVONovo-Nordisk A/S | B | C | C | $48.66 |
| ABTAbbott Laboratories | C | C | B | $116.13 |
| PFEPfizer Inc. | C | D | C | $28.57 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $552.85 |
About NRX Pharmaceuticals, Inc. Common Stock
NRX Pharmaceuticals is a clinical-stage pharmaceutical company developing small-molecule therapeutics for central nervous system disorders and life-threatening pulmonary diseases. The company has commercialized ZYESAMI (Aviptadil) for COVID-related respiratory failure and is advancing NRX-100/101, a sequential treatment regimen for bipolar depression in patients with acute suicidal ideation. Its pipeline targets unmet needs in critical care and psychiatry.